23642-01-5

Upstream product

• 879089-16-4 [Cu₂(OAc)4(H₂O)2] 
• 50-78-2 aspirin 

Downstream Products

• 926044-32-8 Cu₂(ASP)4(3-Br-Py)2 
• 38651-35-3 Cu₂(ASP)4(quinoline)2 
• 130294-24-5 (copper(II)(aspirinate)2(nicotinamide)2) 
• 926044-34-0 Cu(ASP)2(3-phenyl-pyridine)2 
• 130294-23-4 (copper(II)(aspirinate)2(diethylamine)2) 
• 130294-19-8 (copper(II)(aspirinate)2(3-picoline)2) 
• 47806-84-8 (copper(II)(aspirinate)2(pyridine)2) 
• 111716-35-9 (copper(II)(aspirinate)2(dimethyl sulfoxide)2) 

Relevant academic research and scientific papers

Thermal behaviour of copper(II) complexes of haloaspirinates

Complexes of Cu(II) with substituted o-acetoxy benzoic acids (5-haloaspirines, X-asp) with and without pyridine (py), of composition [Cu2(X-asp)4] and [Cu(X-asp)2(py)2] have been synthesized and characterized. E

NEUTRAL PHARMACEUTICALS

The invention comprises neutral multi-functionality assemblies of pharmaceuticals comprising an active medicinal functionality, a transition metal functionality, and an ancillary ligand functionality. An exemplary series of mixed-ligand coordination complexes comprised of copper(Il), a drug and an ancillary ligand were made and tested. It is demonstrated that the judicious choice of an ancillary ligand affords a large degree of control over die relative lipophilicity/hydrophiiicity of the complex in relation to the uncomplexed drug molecule. The important factors to be considered in the design of such complexes, such as the additive-constitutive nature of the partition coefficient of the ancillary ligand and the relative size of the two types of ligands are disclosed, and methods of designing neutral multi- functionality assemblies of pharmaceuticals are disclosed.